Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 30Oropharyngeal Neoplasms 21Nasopharyngeal Carcinoma 15Head and Neck Neoplasms 13Prostatic Neoplasms 11Laryngeal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Squamous Cell 8Carcinoma 8Breast Neoplasms 8Rectal Neoplasms 7Mouth Neoplasms 7Hypopharyngeal Neoplasms 7Glioma 6Glioblastoma 6Uterine Cervical Neoplasms 5Papillomavirus Infections 5Esophageal Neoplasms 5Urinary Bladder Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Nasopharyngeal Neoplasms 4Astrocytoma 4Mesothelioma, Malignant 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Endometrial Neoplasms 3Brain Neoplasms 3Tumor Virus Infections 2Tongue Neoplasms 2Thyroid Carcinoma, Anaplastic 2

Interventions

aldesleukin 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Brachytherapy 2Adoptive Transfer 2zimberelimab 1trastuzumab deruxtecan 1talazoparib 1liposomal doxorubicin 1entinostat 1dostarlimab 1bintrafusp alfa protein, human 1belzutifan 1Therapeutic Touch 1Surveys and Questionnaires 1Specimen Handling 1Sonazoid 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Observation 1Nivolumab 1Methods 1Interviews as Topic 1Gemcitabine 1Fluorodeoxyglucose F18 1FAPI-46 1Educational Status 1Early Intervention, Educational 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vaginal Neoplasms × Radiotherapy, Intensity-Modulated × 1 year × Clear all
NCT02466971 2026-05-29

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

National Cancer Institute (NCI)

Phase 3 Active not recruiting
450 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms, Vaginal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡